Showing results (771-780 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.Immunotherapy|September 9, 2020
COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapyCesar Martins da Costa, Zenaide Silva de Souza, Alessandra Corte Real Salgues, et al.Immunotherapy|November 17, 2020
rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapyWenliang Dong, Min Chen, Jiaxue Wang, et al.Immunotherapy|November 18, 2020
A review of secukinumab in psoriasis treatmentScott H Berg, Esther A Balogh, Rima I Ghamrawi, et al.Immunotherapy|October 20, 2020
Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactionsLiwei Liu, Mingya Yang, Qia Xu, et al.Immunotherapy|October 22, 2020
Early change in peripheral CD4+ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancerChang Liu, Yanni Wang, Shuang Li, et al.Immunotherapy|January 4, 2023
Antigen-independent tumor targeting by CBX-12 (alphalex™-exatecan) induces long-term antitumor immunitySophia Gayle, Timothy Paradis, Kelli Jones, et al.Immunotherapy|June 29, 2021
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse modelsEduardo Huarte, Michael Peel, Ashish Juvekar, et al.Immunotherapy|June 29, 2021
Urothelial carcinoma in the era of immune checkpoint inhibitorsNadine Khalife, Claude Chahine, Manal Kordahi, et al.Immunotherapy|June 23, 2021
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanomaAhmad A Tarhini, Ila Joshi, Fiona GarnerPageof 190